The Company has developed a series of innovative devices including those key ones to treat atrial fibrillation, resistant hypertension and bladder cancer, leading the cryotherapies of prevalent diseases in the world. The company's innovation also includes the non-cryo endoscopic clip for anastomosis. All these products have been recognized as “Innovative Medical Devices” by NMPA, and are protected by the patents worldwide.
Consistent focus on the integration of industry, science, and research, and continuously develop innovative products to meet clinical needs
2023年3月29日,宁波胜杰康生物科技有限公司自主创新研发的用于治疗慢阻肺(COPD)的喷雾冷冻消融系统在上海市第十人民医院王昌惠教授团队带领下,成功完成注册临床试验的全国首例入组,为一位慢性阻塞性肺疾病患者进行了经支气管镜喷雾冷冻消融术,手术过程顺利。
2022年12月8日,康沣生物科技(上海)股份有限公司(以下简称“康沣生物”)自主研发的冷冻消融去肾动脉交感神经系统(Cryofocus RDN System)获得了美国FDA授予的突破性器械认定,该系统主要适用于难治性高血压患者。
近日,宁波胜杰康生物科技有限公司自主研发的创新产品内镜吻合夹获得浙江省药品监督管理局批准上市(注册证号:浙械注准20222020390)。该产品于2019年11月进入浙江省第二类创新医疗器械特别审批通道。内镜吻合夹用于内窥镜引导下闭合消化道软组织缺损、穿孔或止血,其由释放器、施夹帽、吻合夹和线钩四部分组成。其中吻合夹由镍钛合金和医用不锈钢丝组成,采用可拆卸结构设计,相较于传统钛夹,该产品具有更广的夹闭范围和更强的夹闭力,有广泛且显著的临床应用价值。